AbbVie Inc. buy William Blair
Start price
29.01.24
/
50%
€152.90
Target price
29.01.25
-
Performance (%)
-1.17%
Price
20:56
€149.66
Summary
This prediction is currently active. With a performance of -1.17%, the BUY prediction by William_Blair is trending in the wrong direction. A total of €1.46 was paid as dividends for this prediction. This prediction currently runs until 29.01.25. The prediction end date can be changed by William_Blair at any time. William_Blair has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| AbbVie Inc. | -2.844% | -2.844% |
| iShares Core DAX® | -0.992% | -3.231% |
| iShares Nasdaq 100 | -0.225% | -3.339% |
| iShares Nikkei 225® | -0.736% | -7.859% |
| iShares S&P 500 | -0.509% | -2.979% |
Comments by William_Blair for this prediction
In the thread AbbVie Inc. diskutieren
AbbVie Inc. (NYSE: ABBV) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Ratings data for ABBV provided by MarketBeat